Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes
Özet
© 2019 Informa UK Limited, trading as Taylor & Francis Group.In this study, we report the synthesis of novel tris-chalcones and testing of human carbonic anhydrase I, and II isoenzymes (hCA I, and hCA II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly) inhibitors for the development of novel chalcone structures towards for treatment of some diseases. The compounds demonstrated K i values between 13.6 ± 1.1 and 50.0 ± 17.1 nM on hCA I, 9.9 ± 0.8 and 39.5 ± 15.1 nM on hCA II, 3.1 ± 0.2 and 20.1 ± 1.9 nM on AChE, 4.9 ± 0.4 and 14.7 ± 5.2 nM on BChE and 3.9 ± 0.2 and 22.4 ± 10.7 nM on α-Gly enzymes. The results revealed that novel tris-chalcones can have promising drug potential for glaucoma, leukaemia, epilepsy; Alzheimer’s disease that was associated with the high enzymatic activity of hCA I, hCA II, AChE, and BChE enzymes.
Anahtar kelimeler
Sürdürülebilir Kalkınma Amaçları
-
SKA 3: Sağlıklı Bireyler
Atıf için künye
Burmaoglu, S., YILMAZ, A. O., POLAT, M., Kaya, R., Gülçin, İ., & Algul, O. (2021). Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY, 127(2), 153–161. https://doi.org/10.1080/13813455.2019.1623265
BibTeX
@article{burmaoglu2021-67885,
author = {Burmaoglu, Serdar and YILMAZ, Ali Osman and POLAT, MUHAMMED and Kaya, Ruya and Gülçin, İlhami and Algul, Oztekin},
title = {Synthesis of novel tris-chalcones and determination of their inhibition profiles against some metabolic enzymes},
journal = {ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY},
year = {2021},
volume = {127},
number = {2},
pages = {153--161},
issn = {1381-3455},
doi = {10.1080/13813455.2019.1623265},
url = {https://akademik.atauni.edu.tr/yayinlar/67885-synthesis-of-novel-tris-chalcones-and-determination-of-their-inhibition-profiles}
}